Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2010

01-09-2010 | Progress in Hematology

Pathogenesis of diffuse large B cell lymphoma

Author: Wing (John) C. Chan

Published in: International Journal of Hematology | Issue 2/2010

Login to get access

Abstract

Substantial additional insight has been obtained in the past decade regarding the pathogenesis of diffuse large B cell lymphoma (DLBCL). Distinct subtypes of DLBCL have been defined by gene expression profiling (GEP) and they differ not only in GE profiles but also in the pattern of genetic abnormalities. The ability to correlate corresponding genetic and GEP data markedly facilitates the identification of target genes in regions with copy number abnormalities. Oncogenic pathways are often differentially activated in these different subtypes of DLBCL, suggesting that therapy should be targeted according to these differences. The tumor microenvironment plays a significant role in determining outcome and may be a novel target for therapy. The role of microRNA in lymphomagenesis is increasingly being recognized and mutation of key genes has been demonstrated to drive the activation of the NF-κB pathway and B cell receptor signaling. The pace of discovery will be even more rapid in the near future with the convergence of data from multiple complementary genome-wide studies and technological innovations including the rapid advance in the technology of high-throughput sequencing.
Literature
1.
Swerdlow SH, Campo E. WHO classification: pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.
2.
Iqbal J, Liu Z, et al. Gene expression profiling in lymphoma diagnosis and management. Best Pract Res Clin Haematol. 2009;22(2):191–210.CrossRefPubMed
3.
Ishkanian AS, Malloff CA, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet. 2004;36(3):299–303.CrossRefPubMed
4.
Bea S, Zettl A, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106(9):3183–90.CrossRefPubMed
5.
Lenz G, Wright GW, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105(36):13520–5.CrossRefPubMed
6.
7.
8.
9.
10.
Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood. 2006;108(12):3646–53.CrossRefPubMed
11.
Eis PS, Tam W, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005;102(10):3627–32.CrossRefPubMed
12.
Garzon R, Volinia S, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183–9.CrossRefPubMed
13.
Malumbres R, Sarosiek KA, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 2009;113(16):3754–64.CrossRefPubMed
14.
Zhang J, Jima DD, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood. 2009;113(19):4586–94.CrossRefPubMed
15.
Zhang L, Huang J, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA. 2006;103(24):9136–41.CrossRefPubMed
16.
Alizadeh AA, Eisen MB, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.CrossRefPubMed
17.
Rosenwald A, Wright G, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47.CrossRefPubMed
18.
Rosenwald A, Wright G, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–62.CrossRefPubMed
19.
Savage KJ, Monti S, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871–9.CrossRefPubMed
20.
Karnan S, Tagawa H, et al. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2004;39(1):77–81.CrossRefPubMed
21.
Kobayashi T, Yamaguchi M, et al. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5− diffuse large B-cell lymphomas. Cancer Res. 2003;63(1):60–6.PubMed
22.
Niitsu, N., M. Okamoto, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010
23.
Yamaguchi M, Nakamura N, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93(8):1195–202.CrossRefPubMed
24.
Iqbal J, Sanger WG, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165(1):159–66.PubMed
25.
Iqbal J, Greiner TC, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007;21(11):2332–43.CrossRefPubMed
26.
Brandt VL, Roth DB. G.O.D.’s Holy Grail: discovery of the RAG proteins. J Immunol. 2008;180(1):3–4.PubMed
27.
Deriano L, Stracker TH, et al. Roles for NBS1 in alternative nonhomologous end-joining of V(D)J recombination intermediates. Mol Cell. 2009;34(1):13–25.CrossRefPubMed
28.
Lee GS, Neiditch MB, et al. RAG proteins shepherd double-strand breaks to a specific pathway, suppressing error-prone repair, but RAG nicking initiates homologous recombination. Cell. 2004;117(2):171–84.CrossRefPubMed
29.
Tsai AG, Lieber MR. Mechanisms of chromosomal rearrangement in the human genome. BMC Genomics. 2010;11(Suppl 1):S1.CrossRefPubMed
30.
Peled JU, Kuang FL, et al. The biochemistry of somatic hypermutation. Annu Rev Immunol. 2008;26:481–511.CrossRefPubMed
31.
Cattoretti G, Mandelbaum J, et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res. 2009;69(22):8686–92.CrossRefPubMed
32.
Pasqualucci L, Neumeister P, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341–6.CrossRefPubMed
33.
Liu M, Duke JL, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature. 2008;451(7180):841–5.CrossRefPubMed
34.
Lenz G, Nagel I, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007;204(3):633–43.CrossRefPubMed
35.
Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87:163–208.CrossRefPubMed
36.
Lenz G, Wright G, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–23.CrossRefPubMed
37.
Gilmore TD. Role of rel family genes in normal and malignant lymphoid cell growth. Cancer Surv. 1992;15:69–87.PubMed
38.
Lenz G, Davis RE, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676–9.CrossRefPubMed
39.
Compagno M, Lim WK, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717–21.CrossRefPubMed
40.
Honma K, Tsuzuki S, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009;114(12):2467–75.CrossRefPubMed
41.
Hailfinger S, Lenz G, et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2009;106(47):19946–51.PubMed
42.
Dunleavy K, Pittaluga S, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069–76.CrossRefPubMed
43.
Butler MP, Iida S, et al. Alternative translocation breakpoint cluster region 5′ to BCL-6 in B-cell non-Hodgkin’s lymphoma. Cancer Res. 2002;62(14):4089–94.PubMed
44.
Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8(1):22–33.CrossRefPubMed
45.
Basso K, Saito M, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood. 2010;115(5):975–84.CrossRefPubMed
46.
Ranuncolo SM, Wang L, et al. BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner. J Biol Chem. 2008;283(33):22565–72.CrossRefPubMed
47.
Pasqualucci L, Migliazza A, et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood. 2003;101(8):2914–23.CrossRefPubMed
48.
Saito M, Gao J, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell. 2007;12(3):280–92.CrossRefPubMed
49.
Cattoretti G, Pasqualucci L, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell. 2005;7(5):445–55.CrossRefPubMed
50.
Cerchietti LC, Lopes EC, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2009;15(12):1369–76.CrossRefPubMed
51.
Polo JM, Dell’Oso T, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med. 2004;10(12):1329–35.CrossRefPubMed
52.
Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol. 2008;26:133–69.CrossRefPubMed
53.
Pasqualucci L, Compagno M, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006;203(2):311–7.CrossRefPubMed
54.
Tam W, Gomez M, et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood. 2006;107(10):4090–100.CrossRefPubMed
55.
Lam LT, Wright G, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111(7):3701–13.CrossRefPubMed
56.
Melzner I, Bucur AJ, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105(6):2535–42.CrossRefPubMed
57.
Mestre C, Rubio-Moscardo F, et al. Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. Leukemia. 2005;19(6):1082–4.CrossRefPubMed
58.
Ilangumaran S, Rottapel R. Regulation of cytokine receptor signaling by SOCS1. Immunol Rev. 2003;192:196–211.CrossRefPubMed
59.
Ritz O, Guiter C, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009;114(6):1236–42.CrossRefPubMed
60.
Shi S, Calhoun HC, et al. JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet. 2006;38(9):1071–6.CrossRefPubMed
61.
Chen L, Monti S, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111(4):2230–7.CrossRefPubMed
62.
Gururajan M, Jennings CD, et al. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006;176(10):5715–9.PubMed
63.
Davis RE, Ngo VN, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.CrossRefPubMed
64.
Friedberg JW, Sharman J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578–85.CrossRefPubMed
65.
Young KH, Leroy K, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008;112(8):3088–98.CrossRefPubMed
66.
Young KH, Weisenburger DD, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007;110(13):4396–405.CrossRefPubMed
67.
Cheung KJ, Horsman DE, et al. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol. 2009;146(3):257–69.CrossRefPubMed
68.
Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 1999;18(1):22–7.CrossRefPubMed
69.
Calin GA, Sevignani C, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101(9):2999–3004.CrossRefPubMed
70.
He L, Thomson JM, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828–33.CrossRefPubMed
71.
Xiao C, Srinivasan L, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4):405–14.CrossRefPubMed
72.
Chang TC, Yu D, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40(1):43–50.CrossRefPubMed
73.
Takahashi H, Feuerhake F, et al. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res. 2006;12(11 Pt 1):3265–71.CrossRefPubMed
74.
Cimmino A, Calin GA, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102(39):13944–9.CrossRefPubMed
75.
Moller C, Alfredsson J, et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood. 2005;106(4):1330–6.CrossRefPubMed
76.
Dave SS, Fu K, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431–42.CrossRefPubMed
77.
Rimsza LM, Roberts RA, et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood. 2006;107(3):1101–7.CrossRefPubMed
78.
Roberts RA, Wright G, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 2006;108(1):311–8.CrossRefPubMed
79.
Gross S, Walden P. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Immunol Lett. 2008;116(1):7–14.CrossRefPubMed
80.
Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904–12.CrossRefPubMed
81.
Dolcetti R, Boiocchi M. Cellular and molecular bases of B-cell clonal expansions. Clin Exp Rheumatol. 1996;14(Suppl 14):S3–13.PubMed
82.
Pound JD, Gordon J. Maintenance of human germinal center B cells in vitro. Blood. 1997;89(3):919–28.PubMed
83.
Wiesner M, Zentz C, et al. Conditional immortalization of human B cells by CD40 ligation. PLoS One. 2008;3(1):e1464.CrossRefPubMed
84.
Gratzinger D, Zhao S, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest. 2008;88(1):38–47.CrossRefPubMed
Metadata
Title
Pathogenesis of diffuse large B cell lymphoma
Author
Wing (John) C. Chan
Publication date
01-09-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0602-0

Other articles of this Issue 2/2010

International Journal of Hematology 2/2010 Go to the issue

Progress in Hematology

Genomic profiles in B cell lymphoma

Case Report

Pleuric presentation of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: a case report and a review of the literature

Original Article

Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor

Case Report

Primary bone angiosarcoma in a patient with Gaucher disease

Case Report

IgG-associated immune thrombocytopenia in Waldenström macroglobulinemia

Original Article

Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits